Drug delivery company IntelGenx (CVE:IGX) missed expectations on Wall Street yesterday with its second quarter results.
The Quebec-based company posted a net loss of -$550,000 on sales of $1.1 million for the 3 months ended June 30, paring its losses by 32% on sales growth of 64% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post IntelGenx misses Q2 sales, earnings estimates appeared first on MassDevice.